REGN Sentiment Analysis
We collect and analyze sentiment surrounding REGN stock to help you make informed investment decisions.
Regeneron Pharmaceuticals REGN Faces Securities Class Action After Losing 9 Billion Value Following Q3 2024 Earnings Report Hagens Berman
Published on January 9, 2025
Regeneron Pharmaceuticals, Inc....
Regeneron Pharmaceuticals Sets Q4 and Full Year 2024 Earnings Release for February 4
Published on January 8, 2025
Regeneron Pharmaceuticals, Inc....
Regeneron Pharmaceuticals Skyrockets with 89% Return in the Last Five Years
Published on January 7, 2025
Regeneron Pharmaceuticals Inc....
Regeneron Pharmaceuticals Inc. Continues to Impress Investors with Strong Financial Performance
Published on January 6, 2025
Regeneron Pharmaceuticals Inc....
Regeneron Pharmaceuticals: A Strong Performer with Promising Financials
Published on January 5, 2025
Regeneron Pharmaceuticals, Inc....
Regeneron Pharmaceuticals Inc.: A Strong Investment Opportunity for Shareholders
Published on January 4, 2025
Regeneron Pharmaceuticals Inc....
Regeneron Pharmaceuticals: A Promising Future with Strong Returns
Published on January 3, 2025
Regeneron Pharmaceuticals, Inc....
Regeneron Pharmaceuticals: An Impressive 89% Return Over the Last Five Years
Published on January 2, 2025
Regeneron Pharmaceuticals, Inc....
REGN Regeneron Pharmaceuticals: A Promising Investment Opportunity
Published on January 2, 2025
Regeneron Pharmaceuticals, Inc....
Regeneron Pharmaceuticals: A Promising Future Ahead
Published on January 2, 2025
Regeneron Pharmaceuticals, Inc....
Regeneron Pharmaceuticals: Discoveries and Innovations Driving Growth
Published on January 2, 2025
Regeneron Pharmaceuticals, Inc....
Regeneron Pharmaceuticals Continues to Impress Investors with Strong Returns
Published on January 2, 2025
In the past five years, Regeneron Pharmaceuticals (NASDAQ:REGN) has delivered a solid return of 89%, making it a favorable choice for investors. The company has consistently shown promising growth and innovation in the biopharmaceutical industry. Wit...
Regeneron Pharmaceuticals Inc. Shows Impressive 89% Return for Investors
Published on January 1, 2025
Regeneron Pharmaceuticals, Inc....
Regeneron Pharmaceuticals: A Promising Future for Investors
Published on January 1, 2025
Regeneron Pharmaceuticals, Inc....
Regeneron Pharmaceuticals, Inc.: Groundbreaking Discoveries in Drug Development
Published on January 1, 2025
Regeneron Pharmaceuticals, Inc....
Regeneron Pharmaceuticals Inc. Shows Impressive Growth and Promising Future
Published on January 1, 2025
Regeneron Pharmaceuticals, Inc....
REGENERON PHARMACEUTICALS, INC. Hits Forecast Price Target with 16.62% Profit: A Deep Dive into QuantWave's Success
Published on October 31, 2024
On October 8, 2024, QuantWave's forecast for REGENERON PHARMACEUTICALS, INC. signaled a short direction with a price of 1002....
REGENERON PHARMACEUTICALS, INC. Hits QuantWave Forecast Target With 17.54% Profit
Published on October 31, 2024
REGENERON PHARMACEUTICALS, INC....
Regeneron Pharmaceuticals, Inc. Hits QuantWave's Forecast Price Target with 16.62% Profit
Published on October 31, 2024
Regeneron Pharmaceuticals, Inc. recently achieved the price target forecast set by QuantWave, marking a 16....
REGENERON PHARMACEUTICALS, INC. Hits QuantWave Forecast Price Target with Profit of 17.54%
Published on October 31, 2024
REGENERON PHARMACEUTICALS, INC....
REGENERON PHARMACEUTICALS, INC. Stock Hits QuantWave Forecast Price Target with 15.65% Profit
Published on August 27, 2024
REGENERON PHARMACEUTICALS, INC. stock has successfully achieved the price target forecast set by QuantWave on August 27, 2024....
REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 14.57% Profit Margin
Published on August 19, 2024
On July 2nd, 2024, QuantWave issued a forecast signal for REGENERON PHARMACEUTICALS, INC....
REGENERON PHARMACEUTICALS, INC. Hits QuantWave's Forecast Price Target with a 14.57% Profit Gain
Published on August 19, 2024
REGENERON PHARMACEUTICALS, INC....
REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 19.37% Profit: QuantWave Analysis
Published on August 15, 2024
REGENERON PHARMACEUTICALS, INC. has achieved the price target forecast set by QuantWave, resulting in a profit of 19.37%....
REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 18.25% Profit
Published on August 15, 2024
QuantWave's forecast for REGENERON PHARMACEUTICALS, INC....